NZ726488A - Compositions and methods for transmucosal absorption - Google Patents

Compositions and methods for transmucosal absorption

Info

Publication number
NZ726488A
NZ726488A NZ726488A NZ72648813A NZ726488A NZ 726488 A NZ726488 A NZ 726488A NZ 726488 A NZ726488 A NZ 726488A NZ 72648813 A NZ72648813 A NZ 72648813A NZ 726488 A NZ726488 A NZ 726488A
Authority
NZ
New Zealand
Prior art keywords
methods
compositions
transmucosal absorption
agent
amitryptyline
Prior art date
Application number
NZ726488A
Other languages
English (en)
Inventor
Seth Lederman
Giorgio Reiner
Harry Brittain
Original Assignee
Tonix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharmaceuticals Inc filed Critical Tonix Pharmaceuticals Inc
Publication of NZ726488A publication Critical patent/NZ726488A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
NZ726488A 2012-06-15 2013-06-14 Compositions and methods for transmucosal absorption NZ726488A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261660593P 2012-06-15 2012-06-15
US201261667774P 2012-07-03 2012-07-03
US201261725402P 2012-11-12 2012-11-12
US201361792900P 2013-03-15 2013-03-15
NZ631144A NZ631144A (en) 2012-06-15 2013-06-14 Compositions and methods for transmucosal absorption

Publications (1)

Publication Number Publication Date
NZ726488A true NZ726488A (en) 2018-10-26

Family

ID=49758769

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ631144A NZ631144A (en) 2012-06-15 2013-06-14 Compositions and methods for transmucosal absorption
NZ726488A NZ726488A (en) 2012-06-15 2013-06-14 Compositions and methods for transmucosal absorption

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ631144A NZ631144A (en) 2012-06-15 2013-06-14 Compositions and methods for transmucosal absorption

Country Status (26)

Country Link
US (1) US20140171515A1 (enExample)
EP (1) EP2861223B1 (enExample)
JP (5) JP6259452B2 (enExample)
CN (2) CN111388430A (enExample)
AR (1) AR092330A1 (enExample)
AU (2) AU2013274003B2 (enExample)
BR (1) BR112014031394B1 (enExample)
CA (2) CA2876902C (enExample)
DK (1) DK2861223T3 (enExample)
ES (1) ES2929133T3 (enExample)
HR (1) HRP20221325T1 (enExample)
HU (1) HUE060175T2 (enExample)
IL (1) IL236268B (enExample)
LT (1) LT2861223T (enExample)
MX (2) MX2021005317A (enExample)
MY (1) MY194495A (enExample)
NZ (2) NZ631144A (enExample)
PL (1) PL2861223T3 (enExample)
PT (1) PT2861223T (enExample)
RS (1) RS63822B1 (enExample)
SG (2) SG11201408318RA (enExample)
SI (1) SI2861223T1 (enExample)
SM (1) SMT202200436T1 (enExample)
TW (3) TWI683660B (enExample)
WO (1) WO2013188847A1 (enExample)
ZA (1) ZA201500288B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037281T2 (hu) 2009-11-20 2018-08-28 Tonix Pharma Holdings Ltd Eljárás és készítmény poszt-traumás stressz rendellenesség tüneteinek kezelésére ciklobenzaprin alkalmazásával
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
ES2769879T3 (es) 2013-03-15 2020-06-29 Tonix Pharma Holdings Ltd Formulaciones eutécticas de clorhidrato de ciclobenzaprina y manitol
CN107072968B (zh) 2014-09-18 2021-01-12 通尼克斯制药控股有限公司 环苯扎林盐酸盐的低共熔混合物配制剂
CN108024976A (zh) * 2015-07-15 2018-05-11 特兰埃克斯公司 阿米替林用于阻断大脑半通道的用途和用于增强其体内作用的方法
US12337063B2 (en) * 2016-09-02 2025-06-24 University Of Sharjah Formulation for atropine sulfate rapidly-disintegrating sublingual tablets
WO2019014651A1 (en) 2017-07-13 2019-01-17 Tonix Pharmaceuticals Holding Corp. ANALOGUES OF CYCLOBENZAPRINE AND AMITRYPTILENE
CN107496355B (zh) * 2017-08-24 2021-04-30 正大制药（青岛）有限公司 一种盐酸环苯扎林舌下喷雾剂及其制备方法
CN107519142B (zh) * 2017-08-24 2021-02-26 正大制药（青岛）有限公司 一种盐酸环苯扎林舌下片及其制备方法
IL275144B2 (en) * 2017-12-08 2024-12-01 Hoffmann La Roche Pharmaceutical formulation
MX2020006140A (es) 2017-12-11 2020-08-13 Tonix Pharma Holdings Ltd Tratamiento con ciclobenzaprina para la agitacion, psicosis y deterioro cognitivo en la demencia y enfermedades neurodegenerativas.
CN108721240A (zh) * 2018-06-08 2018-11-02 华益药业科技(安徽)有限公司 一种25mg阿米替林薄膜包衣片处方和工艺规程
JP7691739B2 (ja) * 2018-08-20 2025-06-12 トニックス ファーマ ホールディングス リミテッド 急性ストレス障害および外傷後ストレス障害を処置する方法
US20220339124A1 (en) * 2019-09-30 2022-10-27 Cadila Healthcare Limited Intranasal pharmaceutical compositions of cyclobenzaprine
US20210315841A1 (en) * 2020-04-08 2021-10-14 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for sexual dysfunction
MX2023005899A (es) 2020-11-20 2023-08-16 TONIX Pharmaceuticals Holding Corp Tratamiento con ciclobenzaprina para el trastorno por consumo de alcohol.
MX2023006720A (es) 2020-12-07 2023-08-18 TONIX Pharmaceuticals Holding Corp Tratamiento con ciclobenzaprina para fibromialgia.
WO2022170107A2 (en) 2021-02-04 2022-08-11 Tonix Pharmaceuticals Holding Corp. An improved method of assessing clinical response in the treatment of ptsd symptoms
EP4412602A1 (en) 2021-10-06 2024-08-14 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients
JP2025519847A (ja) 2022-06-21 2025-06-26 トニックス ファーマシューティカルズ ホールディング コーポレイション （ＳＡＲＳ）－ＣｏＶ－２感染症の急性期後後遺症（ＰＡＳＣ）のためのシクロベンザプリン処置
WO2025160302A1 (en) 2024-01-25 2025-07-31 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for acute stress reaction or acute stress disorder

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
WO1999018937A1 (en) * 1997-10-16 1999-04-22 Merck & Co., Inc. New cyclobenzaprine composition
DE69904465T2 (de) * 1998-05-14 2003-10-02 Alza Corp., Mountain View Therapie von depressionen
AR025110A1 (es) 1999-08-13 2002-11-06 Vela Pharmaceuticals Inc Metodos y composiciones para tratar o prevenir alteraciones del sueno y enfermedades asociadas usando dosis muy bajas de ciclobenzaprina
BR0013122A (pt) 1999-08-13 2002-04-30 Vela Pharmaceuticals Inc Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
AU2001261744A1 (en) * 2000-05-19 2001-12-03 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
WO2002094229A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of muscle relaxants through an inhalation route
EP1596824A4 (en) * 2003-02-04 2011-11-23 Chrysalis Tech Inc AEROSOL FORMULATIONS AND AEROSOL DISTRIBUTION OF BUSPIRONE, BUPRENORPHINE, TRIAZOLAM, CYCLOBENZAPRINE AND ZOLPIDEM
US20090117054A1 (en) * 2005-03-29 2009-05-07 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US20090148532A1 (en) * 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
JP2009079060A (ja) * 2008-10-15 2009-04-16 Novadel Pharma Inc 極性または非極性の、バッカルスプレーまたはカプセル
US20100266682A1 (en) * 2008-12-10 2010-10-21 Nipun Davar Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
HUE037281T2 (hu) * 2009-11-20 2018-08-28 Tonix Pharma Holdings Ltd Eljárás és készítmény poszt-traumás stressz rendellenesség tüneteinek kezelésére ciklobenzaprin alkalmazásával
US20110319389A1 (en) * 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
ITMI20110558A1 (it) * 2011-04-06 2012-10-07 Campiglio Consulting Srl Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale
ES2769879T3 (es) * 2013-03-15 2020-06-29 Tonix Pharma Holdings Ltd Formulaciones eutécticas de clorhidrato de ciclobenzaprina y manitol

Also Published As

Publication number Publication date
TW201842903A (zh) 2018-12-16
CA3118913A1 (en) 2013-12-19
TWI642429B (zh) 2018-12-01
CA2876902A1 (en) 2013-12-19
ES2929133T3 (es) 2022-11-25
JP2021138765A (ja) 2021-09-16
ZA201500288B (en) 2022-05-25
EP2861223B1 (en) 2022-08-03
JP2017222726A (ja) 2017-12-21
SMT202200436T1 (it) 2023-01-13
TW201408281A (zh) 2014-03-01
JP6259452B2 (ja) 2018-01-10
AU2013274003A1 (en) 2015-02-05
LT2861223T (lt) 2022-12-12
EP2861223A1 (en) 2015-04-22
JP2015519404A (ja) 2015-07-09
BR112014031394B1 (pt) 2022-10-18
PL2861223T3 (pl) 2022-12-12
TW201731494A (zh) 2017-09-16
NZ631144A (en) 2016-12-23
TWI683660B (zh) 2020-02-01
MX382516B (es) 2025-03-13
EP2861223A4 (en) 2016-01-27
JP2019123757A (ja) 2019-07-25
CA2876902C (en) 2021-07-13
SG11201408318RA (en) 2015-01-29
AR092330A1 (es) 2015-04-15
MY194495A (en) 2022-11-30
DK2861223T3 (da) 2022-11-07
JP2024032964A (ja) 2024-03-12
IL236268B (en) 2022-03-01
HRP20221325T1 (hr) 2022-12-23
AU2018241128B2 (en) 2020-05-21
CA3118913C (en) 2024-04-30
SG10201605407TA (en) 2016-08-30
HUE060175T2 (hu) 2023-02-28
AU2018241128A1 (en) 2018-10-25
WO2013188847A1 (en) 2013-12-19
IL236268A0 (en) 2015-02-26
RS63822B1 (sr) 2023-01-31
SI2861223T1 (sl) 2023-01-31
MX2014015436A (es) 2015-07-14
HK1209361A1 (en) 2016-04-01
MX2021005317A (es) 2022-12-16
US20140171515A1 (en) 2014-06-19
PT2861223T (pt) 2022-11-07
BR112014031394A2 (pt) 2017-06-27
CN111388430A (zh) 2020-07-10
CN104684550A (zh) 2015-06-03
AU2013274003B2 (en) 2018-07-05
TWI590820B (zh) 2017-07-11
BR112014031394A8 (pt) 2021-11-03
WO2013188847A8 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
NZ631144A (en) Compositions and methods for transmucosal absorption
IN2014DN09434A (enExample)
GB201118656D0 (en) New compounds
MY188139A (en) Sodium channel modulators for the treatment of pain
PH12014501561A1 (en) Therapeutically active compounds and their methods of use
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
MX366899B (es) Nuevos compuestos.
AU2011328009A8 (en) Compounds and methods for treating pain
IN2012DN06720A (enExample)
MX349004B (es) Nuevos compuestos.
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
PH12013500955A1 (en) Spiro-oxindole mdm2 antagonists
PH12013502261A1 (en) Partially saturated tricyclic compounds and methods of making and using same
PH12014500386A1 (en) Combination treatment for hepatitis c
IN2015DN03219A (enExample)
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
MX2015004362A (es) Derivados de ketamina.
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
EP4302825A3 (en) Pharmaceutical compositions for treatment of inappetence
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
MD20160066A2 (ro) Modulatoare alosterice pozitive ale receptorului nicotinic acetilcolinic
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 JUN 2020 BY SPRUSON + FERGUSON

Effective date: 20190529

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2021 BY CPA GLOBAL

Effective date: 20200604

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2022 BY CPA GLOBAL

Effective date: 20210506

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2023 BY CPA GLOBAL

Effective date: 20220505

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2024 BY CPA GLOBAL

Effective date: 20230504

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240606

ASS Change of ownership

Owner name: TONIX PHARMA LIMITED, IE

Effective date: 20250325

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250515